Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Ter Arkh ; 63(6): 81-6, 1991.
Article in Russian | MEDLINE | ID: mdl-1948755

ABSTRACT

As many as ten patients with terminal uremia on maintenance hemodialysis (MH) performed from 11 to 52 months (28 +/- 4 on the average) were treated with recombinant human erythropoietin (rhERP) manufactured by Cilag (Switzerland). The preparation was injected i.v. in the initial dose 65 U/kg bw thrice a week after each session of MH. If the effect was lacking for 2 weeks, the doze was augmented by 25 U/kg (maximally up to 218 U/kg). Provided the Hb content increased to 100-120 g/l, the maintenance therapy was initiated (108 +/- 13 U/kg). The treatment lasted 17 +/- 2 weeks. As a result, the Hb content in the patients rose from 63.0 to 102.0 g/l, the hematocrit index from 21.2 to 34.4%, the red blood cell count from 2.09 to 3.18 x 10(12)/l; there was a transitory increase of the reticulocyte and platelet counts (from 2.2 to 3.3% and from 172.0 to 284.0 x 10(9)/l) whereas the leukocyte count remained unchanged. It has been demonstrated by the bicycle ergometry data that in addition to the amelioration of the hematological parameters, the patients showed an increase of oxygen consumption at rest, rise of the economy of energy losses at exercise, and a decline of oxygen "cost" of work. According to echocardiography, the patients manifested a reduction of the size of the left heart, of the minute and stroke volumes. In men, the treatment with rhERP brought about libido elevation in the absence of significant alterations in the blood gonadotrophin and testosterone concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Erythropoietin/therapeutic use , Renal Dialysis , Adult , Anemia/blood , Anemia/drug therapy , Anemia/etiology , Anemia/physiopathology , Drug Evaluation , Erythropoietin/adverse effects , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Libido/drug effects , Male , Middle Aged , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Time Factors , Uremia/blood , Uremia/complications , Uremia/physiopathology , Uremia/therapy
4.
Biofizika ; 23(5): 882-7, 1978.
Article in Russian | MEDLINE | ID: mdl-698260

ABSTRACT

Excitation propagation was studied in the papillary muscle of cat's heart and on a mathematical model of homogenous fibre, considerable inhomogeneity being created in the duration of the action potential (DAP) in the left and right part of the object studied. Gradual changes in DAP were observed during excitation propagation period, therefore rough differences in DAP of neighbouring myocardial areas may be excluded. No arrhythmia was observed. It is shwon that the arrhythmia which occurred previously [7] with an increase of DAP in one part of the preparation after EDTA addition was not connected with DAP differences in the neighbouring myocardial areas.


Subject(s)
Arrhythmias, Cardiac/etiology , Heart/physiopathology , Action Potentials , Animals , Arrhythmias, Cardiac/physiopathology , Cats , Computers , Disease Models, Animal , Electrophysiology , Models, Biological , Papillary Muscles/physiopathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...